Associated Neurologists of Southern Connecticut, PC

Fairfield, Connecticut 06824

0 studies enrolling now · 16 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Aura, Cerebral Palsy, Diabetic Neuropathy, Painful, Migraine Headache, Migraine, With or Without Aura, Multiple Sclerosis, Muscle Spasticity, Painful Diabetic Neuropathy, Parkinson Disease, Pediatrics

Studies at this site

• A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) — Completed
• Phase 3 Gene Therapy for Painful Diabetic Neuropathy — Completed
• Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension — Completed
• 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease — Stopped early
• Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations — Stopped early
• An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine — Completed
• BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity — Completed
• BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity — Completed
• Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention — Completed
• Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis — Completed
• Staccato Prochlorperazine in Migraine (Out Patient) — Completed
• Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients — Stopped early
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early